Search | Clinical Trials Finder

Conditions: Atrophic Vaginitis
Interventions: Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more

Conditions: Healthy
Interventions: Norethindrone/Ethinyl Estradiol, FEMCON® Fe; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Menorrhagia
Interventions: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation; Drug · Device
Lead sponsor: Abimbola Famuyide; Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions: Relugolix + Estradiol + Norethindrone Acetate; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Infertility, Hypothalamic Amenorrhea, Hyperprolactinemia
Interventions: Luveris fixed dose, Luveris increasing dose; Drug
Lead sponsor: University Reproductive Associates; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hasbrouck Heights, New Jersey

Conditions: Depression - Major Depressive Disorder, Irritability
Interventions: Kurvelo, Placebo COC; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Interventions: BMS-986500, Palbociclib, Fulvestrant; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Fullerton, California • Greenbrae, California + 11 more

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: fulvestrant, anastrozole; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 856
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more

Conditions: Atrophic Vaginitis
Interventions: Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Breast Cancer
Interventions: Duavee; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Up to 61 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Kansas City, Kansas • Westwood, Kansas

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more

Conditions: Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions: Dronabinol, dextrose; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Menopause
Interventions: estrogen patch, Amino acids, Placebo Patch, Placebo pills; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 48 Years to 60 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometrioma
Interventions: Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Volunteers
Interventions: Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Menopause
Interventions: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 77
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more

Conditions: Hepatitis C Virus
Interventions: Ortho Tri-Cyclen®, BMS-650032; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Postmenopausal Women
Interventions: KSHN001034, Fulvestrant; Drug
Lead sponsor: Kashiv BioSciences, LLC; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Neoplasms, Breast Neoplasms
Interventions: Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream; Drug
Lead sponsor: Prasco LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Denver, Colorado + 23 more

Conditions: Overactive Bladder
Interventions: conjugated estrogen; Drug
Lead sponsor: Loyola University; Other
Eligibility: 55 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk), Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark); Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Mahwah, New Jersey

Conditions: Dyspareunia
Interventions: Estradiol, Imvexxy, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 42
States / cities: Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more

Search by objective public record fields.

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

The Luveris In Vitro Fertilization Trial

Teen Vulnerability to Irritability: Brain and Estrogen Changes

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Individual Differences in Drug Response

Estrogen and Serotonin on Changing Brain Chemistry

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

Drug Interaction Oral Contraceptive Pill (OCP)

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy